Johnson & Johnson (NYSE: JNJ) is set to report its second-quarter financial results before the markets open on Tuesday. The consensus estimates from Thomson Reuters are $2.07 in earnings per share (EPS) and $20.4 billion in revenue. In the same period of last year, the company said it had EPS of $1.83 and $18.84 billion in revenue.
In its most recent report, Johnson & Johnson guided EPS in the range of $8.00 to $8.20 and revenues between $81.0 billion and $81.8 billion for the full year. The consensus estimates are $8.13 in EPS on $81.51 billion in revenue.
Alex Gorsky, board chair and chief executive, commented in the past quarter:
We are pleased with the strong and consistent performance delivered by our colleagues around the world, demonstrated by our sales and EPS growth in the first quarter. Our Pharmaceutical business continues to deliver robust growth and we are pleased with the improvement in our Consumer business. In our Medical Devices businesses, we have areas of leadership and continue to make investments and portfolio choices to improve performance.
Excluding Monday’s move, the stock had underperformed the broad markets, down about 10% year to date. Over the past 52 weeks, the stock was down about 4.5%.
Ahead of the earnings report a few analysts weighed in on the stock:
- Jefferies has a Buy rating with a $145 price target.
- Credit Suisse has a Buy rating and a $151 price target.
- Goldman Sachs has a Neutral rating.
- Sanford Bernstein has a Market Perform rating and a $129 target.
- Citigroup has a Neutral rating with a $134 target price.
- Wells Fargo has an Outperform rating with a $150 price target.
Shares of Johnson & Johnson were last seen down about 1% at $124.88, with a consensus analyst price target of $142.24 and a 52-week trading range of $118.62 to $148.32.
Source: Read Full Article